API | gastric inhibitory polypeptide

gastric inhibitory polypeptide Report issue

Biologics Peptide Experimental

AACT

Active Ingredient History

NOW

Gastric inhibitory polypeptide or gastric inhibitory peptide also known as glucose-dependent insulinotropic polypeptide abbreviated as GIP, is an inhibiting hormone of the secretin family of hormones. While it is a weak inhibitor of gastric acid secretion, its main role is to stimulate insulin secretion. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: No
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

gastric inhibitory polypeptide | glucose dependent insulinotropic polypeptide | glucose-dependent insulinotropic polypeptide

Organizations (10)

Research & Development (10)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Diabetes Mellitus (Phase 1/Phase 2)

Diabetes Mellitus, Type 2 (Phase 1)

Insulin Secretion (Phase 1)

Overview

Highest Phase: Phase 2
# of Trials: 12
# of Trial Organizations: 10

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue